Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-448.09%
operating margin TTM
-450.17%
revenue TTM
120.02 Million
revenue per share TTM
0.69$
valuation ratios | |
|---|---|
| pe ratio | -9.35 |
| peg ratio | 0.75 |
| price to book ratio | 9.04 |
| price to sales ratio | 39.58 |
| enterprise value multiple | -10.27 |
| price fair value | 9.04 |
profitability ratios | |
|---|---|
| gross profit margin | 88.85% |
| operating profit margin | -450.17% |
| pretax profit margin | -448.09% |
| net profit margin | -448.09% |
| return on assets | -60.77% |
| return on equity | -87.19% |
| return on capital employed | -69.37% |
liquidity ratios | |
|---|---|
| current ratio | 7.85 |
| quick ratio | 7.78 |
| cash ratio | 6.99 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 205.01 |
| operating cycle | 406.56 |
| days of payables outstanding | 367.94 |
| cash conversion cycle | 38.63 |
| receivables turnover | 1.81 |
| payables turnover | 0.99 |
| inventory turnover | 1.78 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.19 |
| debt equity ratio | 0.30 |
| long term debt to capitalization | 0.22 |
| total debt to capitalization | 0.23 |
| interest coverage | -41.09 |
| cash flow to debt ratio | -2.47 |
cash flow ratios | |
|---|---|
| free cash flow per share | -1.08 |
| cash per share | 1.87 |
| operating cash flow per share | -1.03 |
| free cash flow operating cash flow ratio | 1.05 |
| cash flow coverage ratios | -2.47 |
| short term coverage ratios | -68.81 |
| capital expenditure coverage ratio | -20.28 |
Frequently Asked Questions
When was the last time Ocular Therapeutix, Inc. (NASDAQ:OCUL) reported earnings?
Ocular Therapeutix, Inc. (OCUL) published its most recent earnings results on 04-11-2025.
What is Ocular Therapeutix, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Ocular Therapeutix, Inc. (NASDAQ:OCUL)'s trailing twelve months ROE is -87.19%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Ocular Therapeutix, Inc. (OCUL) currently has a ROA of -60.77%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did OCUL's net profit margin stand at?
OCUL reported a profit margin of -448.09% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is OCUL's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 7.85 in the most recent quarter. The quick ratio stood at 7.78, with a Debt/Eq ratio of 0.30.